ALMS

Alumis Inc.

Price Chart

Latest Quote

$26.42

Current Price

Previous Close	$24.51
Open	$24.46
Day High	$27.25
Day Low	$24.26
Volume	1,708,853

Fetched: 2026-02-03T11:58:46

Stock Information

Shares Outstanding	117.51M
Total Debt	$37.80M
Cash Equivalents	$377.72M
Revenue	$22.12M
Net Income	$-245.15M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$3.29B
EPS (TTM)	$-2.15
Exchange	NMS

🌐 Visit Website

📊 Custom Metrics & Score

Score: 19/42

Debt to Equity	0.12
Debt to Earnings	-0.10
Current Ratio	6.01
Quick Ratio	5.70

Return on Equity	-113.12%
Avg FCF Growth	44.40%
FCF Yield	-7.80%

Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.

Recent Price History

Date	Close	Volume
2026-02-02	$26.42	1,874,500
2026-01-30	$24.51	1,889,900
2026-01-29	$26.84	1,105,300
2026-01-28	$27.71	3,106,700
2026-01-27	$26.00	1,246,900
2026-01-26	$26.31	2,160,700
2026-01-23	$24.52	2,403,700
2026-01-22	$26.28	1,743,200
2026-01-21	$26.68	1,851,000
2026-01-20	$26.06	2,809,800
2026-01-16	$23.86	1,580,200
2026-01-15	$24.17	2,487,900
2026-01-14	$24.34	4,068,300
2026-01-13	$22.11	4,670,900
2026-01-12	$21.09	4,204,600
2026-01-09	$19.56	6,009,700
2026-01-08	$18.18	9,890,000
2026-01-07	$17.92	9,367,800
2026-01-06	$16.23	65,139,600
2026-01-05	$8.31	1,926,000

About Alumis Inc.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

📰 Latest News

Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials

Insider Monkey • 2026-01-30T14:48:37Z

Huge Insider Buying Now at This Insurance Giant and 2 Biotechs

24/7 Wall St. • 2026-01-19T13:45:46Z

Alumis (ALMS) Is Up 22.0% After Phase 3 Psoriasis Win And $300 Million Equity Raise

Simply Wall St. • 2026-01-19T01:09:43Z

An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million

Motley Fool • 2026-01-17T19:06:59Z

Staar Surgical, Alumis, and More Stocks See Action From Activist Investors

Barrons.com • 2026-01-17T01:39:00Z

HC Wainwright & Co. Hikes Alumis Inc. (ALMS)’s Price Target To $40 From $20, Reiterates Buy Rating

Insider Monkey • 2026-01-15T16:35:29Z

Assessing Alumis (ALMS) Valuation After Positive Phase 3 Psoriasis Data And Strong Share Price Momentum

Simply Wall St. • 2026-01-08T08:13:28Z

ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies

Zacks • 2026-01-07T16:52:00Z

Should You Chase the Rally in Alumis Stock Today?

Barchart • 2026-01-07T16:35:49Z

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

Motley Fool • 2026-01-06T22:32:50Z

Income Statement (Annual)

Revenue

Metric	2024-12-31	2023-12-31	2022-12-31
Total Revenue	$0	$0	$0
Operating Revenue	$0	$0	$0

Expenses

Metric	2024-12-31	2023-12-31	2022-12-31
Total Expenses	$300,754,000	$158,174,000	$113,850,000
Other Income Expense	$-5,499,000	$-187,000	$-72,000
Other Non Operating Income Expenses	$-93,000	$-68,000	$-72,000
Net Non Operating Interest Income Expense	$12,020,000	$3,368,000	$1,992,000
Operating Expense	$300,754,000	$158,174,000	$113,850,000
General And Administrative Expense	$35,200,000	$20,498,000	$12,546,000

Income & Earnings

Metric	2024-12-31	2023-12-31	2022-12-31
Net Income From Continuing Operation Net Minority Interest	$-294,233,000	$-154,993,000	$-111,930,000
Net Interest Income	$12,020,000	$3,368,000	$1,992,000
Interest Income	$12,020,000	$3,368,000	$1,992,000
Normalized Income	$-288,827,000	$-154,874,000	$-111,930,000
Net Income From Continuing And Discontinued Operation	$-294,233,000	$-154,993,000	$-111,930,000
Total Operating Income As Reported	$-300,754,000	$-158,174,000	$-113,850,000
Net Income Common Stockholders	$-294,233,000	$-154,993,000	$-111,930,000
Net Income	$-294,233,000	$-154,993,000	$-111,930,000
Net Income Including Noncontrolling Interests	$-294,233,000	$-154,993,000	$-111,930,000
Net Income Continuous Operations	$-294,233,000	$-154,993,000	$-111,930,000
Pretax Income	$-294,233,000	$-154,993,000	$-111,930,000
Interest Income Non Operating	$12,020,000	$3,368,000	$1,992,000
Operating Income	$-300,754,000	$-158,174,000	$-113,850,000

Per Share Metrics

Metric	2024-12-31	2023-12-31	2022-12-31
Diluted EPS	$-10.38	$-2.99	$-2.91
Basic EPS	$-10.38	$-2.99	$-2.91

Other

Metric	2024-12-31	2023-12-31	2022-12-31
Tax Effect Of Unusual Items	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-292,196,000	$-156,771,000	$-113,600,000
Total Unusual Items	$-5,406,000	$-119,000	-
Total Unusual Items Excluding Goodwill	$-5,406,000	$-119,000	-
Reconciled Depreciation	$3,152,000	$1,284,000	$250,000
EBITDA (Bullshit earnings)	$-297,602,000	$-156,890,000	$-113,600,000
EBIT	$-300,754,000	$-158,174,000	$-113,850,000
Diluted Average Shares	$28,341,866	$51,844,729	$38,410,615
Basic Average Shares	$28,341,866	$51,844,729	$38,410,615
Diluted NI Availto Com Stockholders	$-294,233,000	$-154,993,000	$-111,930,000
Gain On Sale Of Security	$-5,406,000	$-119,000	-
Research And Development	$265,554,000	$137,676,000	$101,304,000
Selling General And Administration	$35,200,000	$20,498,000	$12,546,000
Other Gand A	$35,200,000	$20,498,000	$12,546,000

Fetched: 2026-02-02

Balance Sheet (Annual)

Assets

Metric	2024-12-31	2023-12-31	2022-12-31
Net Tangible Assets	$260,103,000	$-339,260,000	$-195,242,000
Total Assets	$340,992,000	$89,612,000	$108,168,000
Total Non Current Assets	$34,804,000	$36,255,000	$5,613,000
Other Non Current Assets	$1,113,000	$1,031,000	$1,138,000
Current Assets	$306,188,000	$53,357,000	$102,555,000
Other Current Assets	$762,000	$95,000	-
Restricted Cash	$0	$113,000	$206,000
Prepaid Assets	$15,351,000	$3,475,000	$8,984,000
Receivables	$1,812,000	$722,000	$500,000
Taxes Receivable	$1,114,000	$614,000	$500,000
Accrued Interest Receivable	$698,000	$108,000	-
Cash Cash Equivalents And Short Term Investments	$288,263,000	$48,952,000	$92,865,000
Cash And Cash Equivalents	$169,526,000	$45,996,000	$25,610,000

Debt

Metric	2024-12-31	2023-12-31	2022-12-31
Total Debt	$30,722,000	$32,580,000	$1,779,000
Long Term Debt And Capital Lease Obligation	$29,165,000	$30,860,000	$469,000
Current Debt And Capital Lease Obligation	$1,557,000	$1,720,000	$1,310,000

Liabilities

Metric	2024-12-31	2023-12-31	2022-12-31
Total Liabilities Net Minority Interest	$80,889,000	$428,872,000	$303,410,000
Total Non Current Liabilities Net Minority Interest	$29,979,000	$408,001,000	$290,058,000
Other Non Current Liabilities	$814,000	$1,771,000	$4,116,000
Current Liabilities	$50,910,000	$20,871,000	$13,352,000
Payables And Accrued Expenses	$41,588,000	$13,566,000	$8,466,000
Payables	$9,624,000	$1,118,000	$1,720,000
Accounts Payable	$9,624,000	$1,118,000	$1,720,000

Equity

Metric	2024-12-31	2023-12-31	2022-12-31
Common Stock Equity	$260,103,000	$-339,260,000	$-195,242,000
Total Equity Gross Minority Interest	$260,103,000	$-339,260,000	$-195,242,000
Stockholders Equity	$260,103,000	$-339,260,000	$-195,242,000
Gains Losses Not Affecting Retained Earnings	$40,000	$2,000	$-127,000
Other Equity Adjustments	$40,000	$2,000	$-127,000
Retained Earnings	$-658,551,000	$-364,318,000	$-209,325,000
Preferred Securities Outside Stock Equity	$0	$375,370,000	$285,473,000

Other

Metric	2024-12-31	2023-12-31	2022-12-31
Ordinary Shares Number	$54,407,327	$51,844,729	$51,844,729
Share Issued	$54,407,327	$51,844,729	$51,844,729
Tangible Book Value	$260,103,000	$-339,260,000	$-195,242,000
Invested Capital	$260,103,000	$-339,260,000	$-195,242,000
Working Capital	$255,278,000	$32,486,000	$89,203,000
Capital Lease Obligations	$30,722,000	$32,580,000	$1,779,000
Total Capitalization	$260,103,000	$-339,260,000	$-195,242,000
Additional Paid In Capital	$918,610,000	$25,055,000	$14,209,000
Capital Stock	$4,000	$1,000	$1,000
Common Stock	$4,000	$1,000	$1,000
Preferred Stock	$0	$0	-
Long Term Capital Lease Obligation	$29,165,000	$30,860,000	$469,000
Current Capital Lease Obligation	$1,557,000	$1,720,000	$1,310,000
Pensionand Other Post Retirement Benefit Plans Current	$7,765,000	$5,585,000	$3,576,000
Current Accrued Expenses	$31,964,000	$12,448,000	$6,746,000
Net PPE	$33,691,000	$35,224,000	$4,475,000
Accumulated Depreciation	$-4,557,000	$-1,408,000	$-257,000
Gross PPE	$38,248,000	$36,632,000	$4,732,000
Leases	$17,618,000	$17,592,000	$31,000
Other Properties	$17,950,000	$16,360,000	$3,594,000
Machinery Furniture Equipment	$2,680,000	$2,680,000	$529,000
Properties	$0	$0	$0
Other Short Term Investments	$118,737,000	$2,956,000	$67,255,000
Construction In Progress	-	$0	$578,000

Fetched: 2026-02-02

Cash Flow Statement (Annual)

Free Cash Flow

Metric	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow	$-256,810,000	$-134,474,000	$-110,128,000

Operating Activities

Metric	2024-12-31	2023-12-31	2022-12-31
Operating Cash Flow	$-255,078,000	$-129,975,000	$-107,722,000
Cash Flow From Continuing Operating Activities	$-255,078,000	$-129,975,000	$-107,722,000
Operating Gains Losses	$5,411,000	$1,030,000	-

Investing Activities

Metric	2024-12-31	2023-12-31	2022-12-31
Capital Expenditure	$-1,732,000	$-4,499,000	$-2,406,000
Investing Cash Flow	$-113,790,000	$60,472,000	$-68,751,000
Cash Flow From Continuing Investing Activities	$-113,790,000	$60,472,000	$-68,751,000

Financing Activities

Metric	2024-12-31	2023-12-31	2022-12-31
Issuance Of Capital Stock	$451,777,000	$89,778,000	$99,893,000
Financing Cash Flow	$492,367,000	$89,682,000	$101,627,000
Cash Flow From Continuing Financing Activities	$492,367,000	$89,682,000	$101,627,000
Net Other Financing Charges	$40,000,000	$-485,000	-
Net Preferred Stock Issuance	$258,461,000	$89,778,000	$99,893,000
Preferred Stock Issuance	$258,461,000	$89,778,000	$99,893,000
Net Common Stock Issuance	$193,316,000	$0	-
Common Stock Issuance	$193,316,000	-	-
Repurchase Of Capital Stock	-	$0	-

Other

Metric	2024-12-31	2023-12-31	2022-12-31
End Cash Position	$170,632,000	$47,133,000	$26,954,000
Beginning Cash Position	$47,133,000	$26,954,000	$101,800,000
Changes In Cash	$123,499,000	$20,179,000	$-74,846,000
Proceeds From Stock Option Exercised	$590,000	$389,000	$1,734,000
Net Investment Purchase And Sale	$-112,058,000	$64,971,000	$-66,345,000
Sale Of Investment	$128,000,000	$76,250,000	$142,730,000
Purchase Of Investment	$-240,058,000	$-11,279,000	$-209,075,000
Net PPE Purchase And Sale	$-1,732,000	$-4,499,000	$-2,406,000
Purchase Of PPE	$-1,732,000	$-4,499,000	$-2,406,000
Change In Working Capital	$14,760,000	$12,058,000	$-1,916,000
Change In Other Current Liabilities	$-1,858,000	$-144,000	$-820,000
Change In Payables And Accrued Expense	$30,251,000	$7,016,000	$7,257,000
Change In Accrued Expense	$21,745,000	$7,658,000	$5,963,000
Change In Payable	$8,506,000	$-642,000	$1,294,000
Change In Account Payable	$8,506,000	$-642,000	$1,294,000
Change In Prepaid Assets	$-13,633,000	$5,186,000	$-8,353,000
Other Non Cash Items	$60,000	$2,010,000	$950,000
Stock Based Compensation	$19,457,000	$8,625,000	$5,960,000
Asset Impairment Charge	$0	$555,000	$0
Amortization Of Securities	$-3,685,000	$-544,000	$-1,036,000
Depreciation Amortization Depletion	$3,152,000	$1,284,000	$250,000
Depreciation And Amortization	$3,152,000	$1,284,000	$250,000
Gain Loss On Investment Securities	$5,406,000	$119,000	-
Gain Loss On Sale Of PPE	$5,000	$911,000	$0
Net Income From Continuing Operations	$-294,233,000	$-154,993,000	$-111,930,000
Common Stock Payments	-	$0	-

Fetched: 2026-02-02